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The inhalational drug market, especially the generic market, has a tremendous growth potential
globally (GBI Research, 2011; Espicom, 2013; Transperancy: Market Research, 2013). Generics
are drugs that are bioequivalent to the approved drugs. The United States Food and Drug
Administration (FDA) has defined bioequivalence as (U.S. FDA, 2014), “The absence of a
significant difference in the rate and extent to which the active ingredient or active moiety in
pharmaceutical equivalents or pharmaceutical alternatives becomes available at the site of drug
action when administered at the same molar dose under similar conditions in an appropriately
designed study.”
The inhalational route of drug delivery has various advantages (Morgan et al., 1986; Rau, 2005):
1. Delivery of the drugs directly at the site of action.
2. Faster onset of action.
3. Lower systemic concentration and hence lesser adverse drug reactions.
4. Absence of first pass metabolism in m ay cases, permitting use of a lower dose in the formulation;
and more reliable and predictable action.
Generally, to prove bioequivalence of orally inhaled drug products (OIDPs), in-vitro and in-
vivo–pharmacokinetic (PK), and dynamic (PD) studies are required (Committee For Medicinal
Products For Human Use, 2009; Daley-Yates and Parkins, 2011; Lee, 2011; Office of Generic Drugs,
2013). Currently, there is a considerable amount of ongoing debate regarding the universally
acceptable methodology for conducting PK studies for inhaled drugs (Daley-Yates and Parkins,
2011). Nonetheless, PK studies to prove bioequivalence of inhaled drugs play a very important
role toward the goal of ensuring substitutability of generics, especially when in-vitro data and
pharmaceutical data are conflicting (O’Connor et al., 2011).
There has been a lot of interest and discussion among the pharmaceutical companies, regulators,
and academia with regards to bioequivalence studies of OIDPs (Hochhaus et al., 2015). In the
conference co-organized by the University of Florida and the International Pharmaceutical Aerosol
Consortium on Regulation and Science (IPAC-RS) held in March 2014, the main points discussed
were: subject selection for PK studies of OIDPs, PK study design, in-vitro and PK correlations,
regulatory views and so on (Hochhaus et al., 2015).Withmore andmore pharmaceutical companies
wanting to introduce generic OIDPs, it has become imperative to understand certain key concepts
involved in conducting the PK studies for OIDPs.
There exist certain critical issues in conducting the PK studies for proving bioequivalence of
inhaled drugs:
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1. Dose selection: Since the inhalational route delivers the drug
at the site of action, the systemic concentration is very
low, sometimes too low to be detected by the standard
bioanalytical methods. This either requires increasing the
dose of the drug or developing more sensitive methods
of drug assay (Silvestro et al., 2012). Increasing the dose
could endanger the safety of human volunteers, for example,
increased incidence of tremors, palpitations and hypokalemia
due to Salbutamol (Lipworth et al., 1989; Fowler and Lipworth,
2001), anticholinergic side effects due to Glycopyrronium and
Tiotropium (Durham, 2004; Hansel et al., 2005; Loke and
Singh, 2013), etc.
2. Subject selection: Healthy and non-smoking volunteers are to
be selected for the PK study. The reasons for including non-
smokers are ((US) Office on Smoking and Health, 2006; Gold
et al., 1996):
(i) Smokers are more liable to have respiratory morbidities
which may affect the comparative pharmacokinetics
(Zarowitz et al., 1985; Sjosward et al., 2003),
(ii) Smoking leads to induction of various metabolic enzymes
like CYP 1A1 and 1B1 (Kroon, 2007; Olsson et al., 2011),
and
(iii) Smokers have an altered muco-ciliary clearance and local
microenvironment (Scott, 2004).
These factors may introduce intra-subject variability even in
cross-over studies since the cumulative effect of a combination
of these factors may vary in the same individual at different
times. Smokers can be detected objectively by conducting a urine
cotinine test and excluded from the study (Parker et al., 2002;
Jung et al., 2012).
Volunteers can be screened for respiratory diseases by
conducting medical history and examination, chest x-rays and
pulmonary function testing (PFT). PFT can be conducted using
Spirometers or more preferably, Peak Flow Meters (PFM),
especially in the non-hospital settings (Quanjer et al., 1997).
Studies have reported that the PFM may slightly over estimate
the expiratory flow rate, but the difference was not found to
be significant (Quanjer et al., 1997; Gupta and Agarwal, 2007).
Nonetheless, proper procedure for testing with PFM should be
followed, like (Quanjer et al., 1997): application of nose-clip,
asking the subject to form a tight seal around the mouthpiece of
the PFM with their lips and to exhale as forcefully, rapidly and
completely as possible in about 1–2 s. The test may be repeated
for a minimum of three times but no more than eight times
and the gap between the end of maximum inhalation and the
beginning of maximal rapid exhalation should not be more than
2 s (Quanjer et al., 1997).
3. Subject training: This is one of the most important factors for
assuring proper performance of the PFM testing and, more
importantly, for correct and consistent inhalation technique
(Leiva-Fernández et al., 2012; Göris¸ et al., 2013; Rahmati et al.,
2014). The key points to be emphasized while training for
correct inhalation technique are:
(i) Complete exhalation before beginning of inhalation.
(ii) Ensuring a firm seal with the lips around the device
mouth piece.
(iii) For Metered Dose Inhaler (Göris¸ et al., 2013): The
most important thing is co-ordination of actuation and
inhalation. After complete exhalation, the subject should
be asked to breathe in slowly and deeply for 5–10 s. The
device should be actuated while the inhalation is going
on. After this the subject should be asked to hold his/her
breath for 5–10 s and then breathe out normally through
the nose.
(iv) For Dry Powder inhalers (Chrystyn, 2007; Lavorini et al.,
2008): Here, the energy for propelling and inhaling
the drug is provided by the individual, that is, they
are breath actuated. Hence, the inhalation attempt
has to be rapid and deep with quick acceleration
over 3–4 s. After this the subject should be asked to
hold his/her breath for 5–10 s and then breathe out
normally through the nose. The most common mistake
while using a DPI is not completely exhaling before
beginning of inhalation followed by not holding breath
adequately.
Various aids and instruments are available for inhalation training
of patients/ volunteers (Al-Showair et al., 2007; Lavorini et al.,
2010; Yawn et al., 2012; Lavorini, 2013).
4. Other factors:
(i) Use of a spacer with an MDI: Using a spacer an MDI
obviates the need for coordination between inhalation and
actuation and also decreases the deposition of the drug
particles in the oropharynx (Lavorini and Fontana, 2009).
As per the European Agency for Evaluation of Medicinal
Products (EAM) (Committee For Proprietary Medicinal
Products, 2004), if a product has been licensed for use
only with a spacer, the PK studies should have a spacer. If
the product can be used with or without a spacer, two PK
studies would be required, one with and the other without
the spacer. As per our personal communication with a
consultant regarding the U.S. FDA, 2014 requirements,
spacers are not required for PK studies unless the product
is to be used only with spacers.
(ii) Use of charcoal block (Adams et al., 2010): Administering
charcoal suspension at various intervals eliminates the
enteral absorption of the proportion of inhaled drug which
may be swallowed and the systemic concentration reflects
only that fraction of the drug that is absorbed form the
respiratory tract. Use of charcoal block is not mandatory
for PK studies for regulatory submissions, except for EMA
submissions (Lu et al., 2015). If used, the method of
administering charcoal should be adequately validated.
EMA requires two studies: one with and one without
charcoal block (Lu et al., 2015).
To summarize, the following are recommended:
1. Using the least possible dose and developing sensitive
bioanalytical methods.
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2. Selection of healthy and non-smoking volunteers. Their
smoking status can be judged by the urine cotinine test. Their
screening PFT can be done by using PFM as described above.
3. Subject training for correct performance of the PFM test and
inhalation of drug from the MDI/DPI is the most important
aspect. For MDI, steady and gentle inhalation in coordination
with actuation and for DPI rapid, forceful and deep inhalation
is required.
4. Spacers may be used with MDIs if required. If charcoal block is
used, the procedure should be adequately validated.
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